ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Form 6-K — May 22, 2026
Ascentage Pharma Group International released clinical data from multiple trials at the ASCO 2026 conference, signaling progress in its oncology pipeline. The filing also includes results from an extraordinary general meeting where shareholders overwhelmingly approved the audited consolidated financial statements for the year ended December 31, 2025. The board re-elected Dr. Wang Shaomeng and Dr.
Key figures
- Votes for financials
- 85,580,809
- Votes for wang shaomeng
- 85,580,808
- Votes against financials
- 40,000
- Votes for david sidransky
- 85,346,659
- Votes for lu simon dazhong
- 84,501,778
- Votes against wang shaomeng
- 40,000
- Votes against david sidransky
- 274,150
- Votes against lu simon dazhong
- 1,119,030
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.